News Headlines

  1. Abeona Therapeutics Details Pathway For Advancing Lead Clinical Programs And Unveils New Cystic Fibrosis Program
    12/6/2018

    Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, recently announced key pipeline updates during the Company’s 2018 R&D Day.

  2. Intellia Therapeutics And Novartis Expand Cell Therapy Collaboration To Pursue CRISPR/Cas9-Based Genome Editing In Additional Stem Cell Population
    12/6/2018

    Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced an expansion of its existing cell therapy collaboration with Novartis, to include the ex vivo development of innovative cell therapies using certain ocular stem cells.

  3. Wave Life Sciences Announces Positive Phase 1 Results For WVE-210201 In Duchenne Muscular Dystrophy (DMD)
    12/6/2018

    Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that the safety and tolerability data from the WVE-210201 Phase 1 clinical trial in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping support initiation of a Phase 2/3 clinical trial.

  4. Biogen Exercises Option With Ionis To Develop And Commercialize Investigational Treatment BIIB067 For A Subtype Of Familial Amyotrophic Lateral Sclerosis (ALS) Based On Positive Phase 1 Data
    12/6/2018

    Biogen Inc (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Biogen exercised its option to obtain from Ionis a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB067 (IONIS-SOD1RX), an investigational treatment for amyotrophic lateral sclerosis (ALS) with superoxide dismutase 1 (SOD1) mutations.

  5. BeyondSpring Announces Phase 3 Study 105 Of Its Lead Asset Plinabulin For Chemotherapy-Induced Neutropenia Meets Primary Endpoint At Interim Analysis
    12/6/2018

    BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Phase 3 portion of its pivotal Study 105, evaluating its lead asset, Plinabulin, in the 105 enrolled patients treated with docetaxel chemotherapy, has met its primary endpoint of non-inferiority versus Neulasta® for the duration of severe neutropenia (DSN) of the first cycle, with statistical significance in a pre-specified interim analysis.

  6. Preliminary Results From Randomized Phase 2 Trial Demonstrate Trilaciclib Improved Progression-Free Survival In Combination With Chemotherapy In Patients With Metastatic Triple-Negative Breast Cancer
    12/4/2018

    G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced preliminary anti-tumor efficacy and myelopreservation data from its randomized, open-label Phase 2 trial evaluating trilaciclib in combination with chemotherapy as a treatment for metastatic triple-negative breast cancer (mTNBC).

  7. GSK Reaches Agreement To Acquire TESARO, An Oncology Focused Biopharmaceutical Company
    12/3/2018

    GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) today announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire TESARO, an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (£4.0 billion).

  8. TrialScope Unites Industry Leaders To Address Key Issues Of Clinical Trial Disclosure And Transparency At 2018 Strategic Partner Meeting
    11/27/2018

    At its recent Strategic Partner Meeting, TrialScope recognized sponsors and individuals with Clārus Awards. The first annual awards included:

    • 2018 Disclosure & Transparency Vanguard
    • 2018 Disclosure & Transparency Trailblazer
    • 2018 Compliance Leader
  9. PhaseBio Announces Dosing Of First Patient In Phase 2b Clinical Trial Of PB1046 In Pulmonary Arterial Hypertension
    11/27/2018

    PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, with an initial focus on cardiopulmonary disorders, today announced that the first patient in a Phase 2b clinical trial of PB1046 for the treatment of pulmonary arterial hypertension (PAH) has been dosed by Murali Chakinala, M.D., Professor of Medicine at the Washington University School of Medicine (WUSM) and Director of the WUSM and Barnes-Jewish Hospital Pulmonary Hypertension Care Center.

  10. Evelo Enters Into Clinical Trial Collaboration Agreement With Merck
    11/27/2018

    Evelo Biosciences, Inc. (NASDAQ:EVLO) (“Evelo”), a clinical-stage biotechnology company developing monoclonal microbials to engage immune cells in the small intestine and drive changes in systemic biology, today announced that it has entered into a clinical trial collaboration agreement with Merck (known as MSD outside the US and Canada).